Faculty, Staff and Student Publications
Publication Date
5-11-2024
Journal
Journal of Hematology & Oncology
Abstract
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Keywords
Inotuzumab Ozogamicin, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological, Adult, Antineoplastic Combined Chemotherapy Protocols, Antibody-drug conjugate, Clinical trials, Efficacy, Immunotherapy, Lymphoid diseases., Antibody-drug conjugate, Clinical trials, Efficacy, Lymphoid diseases, Immunotherapy
DOI
10.1186/s13045-024-01552-7
PMID
38734670
PMCID
PMC11088766
PubMedCentral® Posted Date
5-11-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons